Tag: clobetasol propionate
-
Formosa Pharmaceuticals and Samil Pharmaceuticals Secure Exclusive Licensing for Clobetasol Propionate Ophthalmic Suspension
Overview of the Licensing Agreement Formosa Pharmaceuticals, a biotechnology-focused company based in Taiwan, has announced a new exclusive licensing agreement with Samil Pharmaceuticals Co., Ltd. The collaboration centers on the commercialization of clobetasol propionate ophthalmic suspension, a corticosteroid treatment designed to address ocular inflammation. The deal marks a strategic partnership aimed at expanding access to…
-
Formosa Pharmaceuticals and Samil Pharmaceuticals Strike Exclusive License for Clobetasol Propionate Ophthalmic Suspension
Strategic Licensing Move Targets Ophthalmic Inflammation Treatments Formosa Pharmaceuticals, a Taiwan-based bioscience company, has announced a landmark licensing agreement with Samil Pharmaceuticals, Co., Ltd. that grants exclusive rights to commercialize clobetasol propionate ophthalmic suspension intended for treating inflammation and related ocular conditions. The collaboration marks a significant step for Formosa as it expands its portfolio…
-
Formosa Licenses Clobetasol Ophthalmic Suspension with Samil for Ocular Inflammation Treatment
Overview Formosa Pharmaceuticals, a Taiwan-based biopharma company, has announced an exclusive licensing agreement with Samil Pharmaceuticals Co., Ltd. for the commercialization of clobetasol propionate ophthalmic suspension. The collaboration aims to bring a potent topical corticosteroid therapy to patients suffering from ocular inflammation, expanding Formosa’s portfolio in ophthalmology and Samil’s international reach. About the Agreement The…